The 2023 Cell & Gene Meeting on the Med was delivered in a hybrid format with live programming available over the course of two days at the Hotel Arts Barcelona. Virtual registrants had access to all content via livestream during the program dates. Additionally, all content was made available on-demand within 24 hours of the live program time for all registrants to view.
7:30am – 9:00am | REGISTRATION
Sponsored by Akron Biotech
8:00am | PARTNERING OPENS
9:00am | GENERAL SESSION
WELCOME REMARKS
{BioCentriq Ballroom}
9:00am – 9:15am
Speakers:
Tim Hunt, CEO, Alliance for Regenerative Medicine (ARM)
Devyn Smith, Ph.D., CEO, Arbor Biotechnologies; Chairman, Alliance for Regenerative Medicine (ARM)
9:15am – 10:15am | CONCURRENT TRACKS
PLENARY SESSION: A NEW ERA FOR ATMPS – COMMERCIALIZING IN THE EU
{BioCentriq Ballroom}
9:15am – 10:15am
Executives from companies with experience commercializing cell and gene therapies in the European Union will describe the current landscape and lessons learned. What are the trends among payers and HTA bodies? What has led to success in establishing patient access? What are the main barriers and opportunities to commercialization in the EU?
Chair:
Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult
Speakers:
Lutz Bonacker, Ph.D., Senior Vice President and General Manager, Commercial Operations Europe, CSL Behring
Emmanuel Chantelot, Vice President, Head of International Policy and Government Affairs, Bristol-Myers Squibb
Chris Fox, President, Novartis Gene Therapies
COMPANY PRESENTATIONS
{Dark Horse Consulting Ballroom}
9:15am – 10:15am
| 9:15am – 9:30am | Cryoport Systems |
| 9:30am – 9:45am | Ray Therapeutics |
| 9:45am – 10:00am | Exothera |
| 10:00am – 10:15am | RoslinCT |
10:15am – 10:45am | MORNING BREAK
Sponsored by Anocca
10:45am – 12:30pm | CONCURRENT TRACKS
COMPANY PRESENTATIONS
{BioCentriq Ballroom}
| 10:45am – 11:00am | IN8bio |
| 11:00am – 11:15am | Autolus Therapeutics |
| 11:15am – 11:30am | Prescient Therapeutics |
| 11:30am – 11:45am | Vor Bio |
| 11:45am – 12:00pm | BlueRock Therapeutics |
| 12:00pm – 12:15pm | Orchard Therapeutics |
| 12:15pm – 12:30pm | Cabaletta Bio |
COMPANY PRESENTATIONS
{Dark Horse Consulting Ballroom}
| 10:45am – 11:00am | AffyXell Therapeutics |
| 11:00am – 11:15am | Kiji Therapeutics |
| 11:15am – 11:30am | Kytopen |
| 11:30am – 11:45am | Resolution Therapeutics |
| 11:45am – 12:00pm | Arbor Biotechnologies |
| 12:00pm – 12:15pm | Aspect Biosystems |
| 12:15pm – 12:30pm | Form Bio |
12:30pm – 1:45pm | LUNCH
Sponsored by Notch Therapeutics
1:45pm – 3:15pm | CONCURRENT TRACKS
THE HOSPITAL EXEMPTION: A NECESSARY SHORTCUT OR THE END OF HIGH REGULATORY STANDARDS?
{BioCentriq Ballroom}
1:45pm – 2:45pm
Chair:
Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics
Speakers:
Gonzalo Calvo Rojas, M.D., Ph.D., Head, Clinical Pharmacology Department and Coordinator of Advanced Therapies, Hospital Clinic of Barcelona
Paschalia Koufokotsiou, Policy Officer, Pharmaceutical and Health Policy, DG SANTE, European Commission
Christopher Vann, Senior Vice President and Chief Operating Officer, Autolus Therapeutics
COMPANY PRESENTATIONS
{Dark Horse Consulting Ballroom}
| 1:45pm – 2:00pm | Forge Biologics |
| 2:00pm – 2:15pm | Affini-T Therapeutics |
| 2:15pm – 2:30pm | NKILT Therapeutics |
| 2:30pm – 2:45pm | Notch Therapeutics |
SPOTLIGHT SESSION: THE FUTURE OF MRNA FOR CELL AND GENE THERAPIES
{BioCentriq Ballroom}
2:45pm – 3:15pm
Speaker:
Paolo Martini, Ph.D., Chief Scientific Officer International Therapeutics Research Centers; Founder, Moderna Rare Diseases, Moderna
COMPANY PRESENTATIONS
{Dark Horse Consulting Ballroom}
| 2:45pm – 3:00pm | Avectas |
| 3:00pm – 3:15pm | Andelyn Biosciences |
3:15pm – 3:45pm | AFTERNOON BREAK
Sponsored by Anocca
3:45pm – 5:30pm | CONCURRENT TRACKS
ROI: WHAT INVESTORS WANT TO SEE IN THE EUROPEAN ATMP ECOSYSTEM
{BioCentriq Ballroom}
3:45pm – 4:45pm
Chair:
Phil Vanek, Ph.D., Chief Technology Officer and Partner, Gamma Biosciences
Speakers:
Geoffroy de Ribains, Managing Partner, AdBio partners
Lucia Faccio, Ph.D., Partner, Sofinnova Partners
Edward Hodgkin, Ph.D., Senior Partner, Syncona Investment Management; CEO, Resolution Therapeutics
Jordi Xiol, Ph.D., Partner, Ysios Capital
COMPANY PRESENTATIONS
{Dark Horse Consulting Ballroom}
| 3:45pm – 4:00pm | TrakCel |
| 4:00pm – 4:15pm | L7 Informatics |
| 4:15pm – 4:30pm | PeterBio |
| 4:30pm – 4:45pm | TreeFrog Therapeutics |
EXTRAORDINARY SCIENCE: NAVIGATING CGTX DEVELOPMENT IN 2023 WORKSHOP
Sponsored by Precision ADVANCE
{BioCentriq Ballroom}
4:45pm – 5:30pm
This panel will feature insights from industry leaders on the future of advanced medicines including:
Chair:
Anshul Mangal, President, Project Farma and Precision ADVANCE
Speakers:
Phil Cyr, Senior Vice President, Precision Value & Health
Robin Kenselaar, Senior Vice President and General Manager, EMEA, Orchard Therapeutics
Kim Nguyen, Ph.D., Chief Technical Officer, Affini-T Therapeutics
Devyn Smith, Ph.D., CEO, Arbor Biotechnologies; Chairman, Alliance for Regenerative Medicine (ARM)
Philip Toleikis, Ph.D., President and CEO, Sernova Corp
TRANSFORMING THE WILD FRONTIER – INDUSTRIALIZATION OF ADVANCED THERAPIES WORKSHOP
Sponsored by Charles River Laboratories
{Dark Horse Consulting Ballroom}
4:45pm – 5:30pm
As the cell and gene therapy field transitions from the wild frontier into the industrial age, one of the key challenges ahead will be how to scale a therapeutic candidate efficiently and cost-effectively to meet patient population demand. This session will discuss insights from evaluating new technologies, to their implementation, and moving to high throughput manufacturing for taking advanced therapies from the clinic to the market.
Chair:
Matthew Hewitt, Ph.D., Vice President, Technical Officer Cell and Gene Therapy and Biologics, Charles River Laboratories
Speakers:
Lisa Deschamps, CEO and Executive Board Member, AviadoBio
Pedro Gonzalez-Alegre, M.D., Ph.D., Head of Gene Therapy Research, Spark Therapeutics
John Hadden, CEO and Co-founder, ViroCell Biologics
Sven Kili, M.D., CEO and Board Member, Antion Biosciences
5:30pm | PROGRAM AND PARTNERING CLOSES
5:30pm – 8:30pm | NETWORKING BASH
Sponsored by Bio-Techne and ScaleReady
7:30am – 9:00am | REGISTRATION
Sponsored by Akron Biotech
8:00am | PARTNERING OPENS
9:00am | GENERAL SESSION
CLOSING REMARKS
{BioCentriq Ballroom}
9:00am – 9:15am
Speaker:
Tim Hunt, CEO, Alliance for Regenerative Medicine (ARM)
9:15am – 10:15am | CONCURRENT TRACKS
HOPES AND CONCERNS: HOW PATIENTS AND CAREGIVERS APPROACH ATMPS
{BioCentriq Ballroom}
9:15am – 10:15am
Cell and gene therapies represent hope for patients with few, or no, treatment options. But patients and their caregivers also have questions, and sometimes concerns, about how the therapies work, what the risks are, and the commitment required to undergo treatment. Prominent representatives from the patient community will share perspectives on how patients approach ATMPs.
Chair:
Bob Smith, Senior Vice President, Global Gene Therapy Business, Pfizer
Speakers:
Matt Bolz-Johnson, Mental Health Lead and Healthcare Advisor, EURORDIS
Brian O’Mahony, Chief Executive, Irish Haemophilia Society
Christos Sotirelis, Ph.D., International Relations Lead, Comitato Famiglie Talassemici (CFT) Florence
Durhane Wong-Rieger, Ph.D., Board Chair, Rare Diseases International
10:15am – 10:30am | MORNING BREAK
Sponsored by Anocca
10:30am – 12:30pm | CONCURRENT TRACKS
LEADER’S FORUM ON EU HEALTH TECHNOLOGY ASSESSMENT FOR ATMPS
{BioCentriq Ballroom}
10:30am – 11:30am
The European HTA Regulation has introduced an EU-level Joint Clinical Assessment of the benefits of ATMPs, to inform national reimbursement decisions. The requirements and expectations that will form the basis for these assessments will have far-reaching impact on patient access to these treatments. This session will examine the objectives and implications of Joint Clinical Assessment from the perspectives of the Commission, patients, developers and HTAs, and discuss the conditions for a workable system.
Chair:
Nicholas Gertler, Co-Founder, Galen/Atlantica
Speakers:
François Houÿez, Information and Access to Therapies Director and Health Policy Advisor, EURORDIS
Carole Longson, Vice Chair, Medicines Discovery Catapult; Former Executive Director, NICE
Marco Marchetti, M.D., Head, HTA Agenas Italy; Co-chair, EU HTA Coordination Group
Francis Pang, Senior Vice President, Global Market Access and Geographic Expansion, Orchard Therapeutics
COMPANY PRESENTATIONS
{Dark Horse Consulting Ballroom}
| 10:30am – 10:45am | Cellistic |
| 10:45am – 11:00am | Carisma Therapeutics |
| 11:00am – 11:15am | Luminary Therapeutics |
| 11:15am – 11:30am | Antion Biosciences |
COMPANY PRESENTATIONS
{BioCentriq Ballroom}
| 11:30am – 11:45am | Xintela |
| 11:45am – 12:00pm | Novo Nordisk |
| 12:00pm – 12:15pm | Cynata Therapeutics |
| 12:15pm – 12:30pm | GENETHON |
COMPANY PRESENTATIONS
{Dark Horse Consulting Ballroom}
| 11:30am – 11:45am | Anocca |
| 11:45am – 12:00pm | ElevateBio |
| 12:00pm – 12:15pm | SaxoCell – Fraunhofer IZI |
| 12:15pm – 12:30pm | Emendo Biotherapeutics |
12:30pm – 1:30pm | LUNCH
Sponsored by Dark Horse Consulting
1:30pm – 3:00pm | CONCURRENT TRACKS
COMPANY PRESENTATIONS
{BioCentriq Ballroom}
| 1:30pm – 1:45pm | Coave Therapeutics |
| 1:45pm – 2:00pm | Oxford Biomedica |
COMPANY PRESENTATIONS
{Dark Horse Consulting Ballroom}
| 1:30pm – 1:45pm | Accelerated Biosciences |
| 1:45pm – 2:00pm | MaxCyte |
THE PIONEER’S TAX: CHALLENGES AND OPPORTUNITIES OF BEING AT THE FOREFRONT OF INNOVATION
{BioCentriq Ballroom}
2:00pm – 3:00pm
In any industry, significant challenges exist to pioneers who bring forward new and highly disruptive technology. Our panel will explore this topic for cutting edge gene and cell therapies.
Chair:
Jeff Ross, Ph.D., CEO, Miromatrix Medical
Speakers:
Andrew Bellinger, M.D., Ph.D., Chief Scientific Officer and Chief Medical Officer, Verve Therapeutics
Seth Ettenberg, Ph.D., President and CEO, BlueRock Therapeutics
Johanna Rossell, Chief Commercial Officer, Enzyvant Therapeutics
Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer, Intellia Therapeutics
COMPANY PRESENTATIONS
{Dark Horse Consulting Ballroom}
| 2:00pm – 2:15pm | AviadoBio |
| 2:15pm – 2:30pm | Dyno Therapeutics |
| 2:30pm – 2:45pm | Life Edit Therapeutics |
| 2:45pm – 3:00pm | Nanite |
3:00pm – 3:15pm | AFTERNOON BREAK
Sponsored by Anocca
3:15pm – 5:00pm | CONCURRENT TRACKS
COMPANY PRESENTATIONS
{BioCentriq Ballroom}
| 3:15pm – 3:30pm | BioCentriq |
| 3:30pm – 3:45pm | Miromatrix |
| 3:45pm – 4:00pm | Sernova |
COMPANY PRESENTATIONS
{Dark Horse Consulting Ballroom}
| 3:15pm – 3:30pm | VectorY Therapeutics |
| 3:30pm – 3:45pm | VERIGRAFT |
| 3:45pm – 4:00pm | PDC*line pharma |
PLANNING FOR CGT COMMERCIAL READINESS: ADAPTIVE MANUFACTURING STRATEGY
{BioCentriq Ballroom}
4:00pm – 5:00pm
In the dynamic environment of the cell and gene therapy space, ensuring future commercial success involves flexibility in decision making during the planning for commercial scale-up. This expert panel will discuss adaptive manufacturing strategy through every stage of development, from building predictive scale-down models, to investment in technological innovation, data analytics, and automation.
Chair:
John Maslowski, Chief Commercial Officer, Forge Biologics
Speakers:
Øystein Åmellem, Ph.D., Director, Cell Therapy, Thermo Fisher Scientific
Robert Ang, President and CEO, Vor Bio
Marcos Langtry, Global Head of Commercial Development, Cell Therapy, Lonza
Barbara Sanders, Ph.D., Chief Technology Officer, VectorY Therapeutics
COMPANY PRESENTATIONS
{Dark Horse Consulting Ballroom}
| 4:00pm – 4:15pm | Atamyo Therapeutics |
| 4:15pm – 4:30pm | CEVEC |
| 4:30pm – 4:45pm | SNBTS |
| 4:45pm – 5:00pm | Mekonos |
5:00pm | PROGRAM AND PARTNERING CLOSES
5:00pm – 7:00pm | WINE TASTING RECEPTION
Sponsored by Oxford Biomedica
8:30am – 12:00pm | ARM EU COMMITTEE MEETINGS
Open to ARM Members Only
EUROPEAN ADVISORY COMMITTEE
{Saló Picasso}
8:30am – 10:00am
EUROPEAN REGULATORY AFFAIRS WORKSHOP
{Saló Picasso}
10:00am – 12:00pm
EUROPEAN MARKET ACCESS AND VALUE COMMITTEE
{Saló Albéniz}
10:00am – 11:00am
April 12-14, 2023
Hotel Arts Barcelona
Marina 19-21
Barcelona, Spain
